Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetyl-CoA acetyltransferase 1 (ACAT1) is a mitochondrial enzyme and a member of the Class II thiolase family that catalyzes the reversible condensation of two molecules of acetyl-CoA to form acetoacetyl-CoA, a key reaction in ketogenesis and cholesterol biosynthesis[1][5][6][8]. ACAT1 is widely expressed in human tissues and plays an essential role in mitochondrial beta-oxidation of fatty acids, energy metabolism, and maintaining acetyl-CoA homeostasis[1][7][8]. Genetic defects in ACAT1 cause beta-ketothiolase deficiency, which can lead to recurrent episodes of ketoacidosis and other metabolic derangements. ACAT1 is distinct from Acyl-CoA:cholesterol acyltransferases (also sometimes abbreviated as ACAT but encoded by different genes, such as SOAT1 and SOAT2); the canonical name outlined here refers specifically to mitochondrial acetyl-CoA acetyltransferase 1[1][5][8].
Catalyzes the reversible formation of acetoacetyl-CoA from two molecules of acetyl-CoA; drugs would likely act as inhibitors or activators of thiolase activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetyl-CoA acetyltransferase 1 (ACAT1).